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Moyamoya is a cerebrovascular condition characterized by a progressive stenosis of the terminal part of the internal carotid arteries
(ICAs) and the compensatory development of abnormal ‘‘moyamoya’’ vessels. The pathophysiological mechanisms of this condition,
which leads to ischemic and hemorrhagic stroke, remain unknown. It can occur as an isolated cerebral angiopathy (so-called moyamoya
disease) or in association with various conditions (moyamoya syndromes). Here, we describe an autosomal-recessive disease leading to
severe moyamoya and early-onset achalasia in three unrelated families. This syndrome is associated in all three families with homozy-
gous mutations in GUCY1A3, which encodes the a1 subunit of soluble guanylate cyclase (sGC), the major receptor for nitric oxide (NO).
Platelet analysis showed a complete loss of the soluble a1b1 guanylate cyclase and showed an unexpected stimulatory role of sGCwithin
platelets. The NO-sGC-cGMP pathway is a major pathway controlling vascular smooth-muscle relaxation, vascular tone, and vascular
remodeling. Our data suggest that alterations of this pathway might lead to an abnormal vascular-remodeling process in sensitive
vascular areas such as ICA bifurcations. These data provide treatment options for affected individuals and strongly suggest that inves-
tigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and non-
syndromic moyamoya.Introduction
Moyamoya (MIM 252350, 607151, and 608796) is a
cerebrovascular condition characterized by a progressive
stenosis of the terminal part of the supraclinoid internal
carotid arteries (ICAs) and their bifurcation proximal
branches.1,2 This disease is associated with the compensa-
tory development of abnormally thin and fragile collateral
vessels at the base of the brain (‘‘moyamoya’’ vessels).
Reduced cerebral blood flow and rupture of the fragile
collateral vessels lead to ischemic and hemorrhagic stroke
in moyamoya-affected children and adults. Pathological
analysis has shown that a marked decrease in the outer
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The Amean eccentric fibrocellular thickening of the intima (which
contains proliferating smooth-muscle actin-positive cells),
luminal thrombosis, and thinning of the media vascular
layer.3
Despite a great deal of investigation, the molecular eti-
ology and pathogenesis of moyamoya angiopathy remain
unclear.4 Moyamoya angiopathy might be associated
with well-defined acquired or genetic conditions.1,2
These conditions, known as moyamoya syndromes, are
distinct from moyamoya disease (MMD), an idiopathic
disorder in which the sole manifestation of the disease
is the cerebral angiopathy. The prevalence of this dis-
order is close to 3/100,000 in East Asia and ten times
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Figure 1. Identification of the Causative
Mutations in Three Families Affected by
a Syndrome Associating Moyamoya with
Achalasia
(A) Genealogical trees of families F1, F2,
and F3. Circles represent females, and
squares represent males. Black-filled sym-
bols indicate affected individuals, and
empty symbols indicate healthy members.
Asterisks show individuals with both
moyamoya (or intracranial angiopathy)
and achalasia. Circles and squares with a
symbol indicate individuals from
whom blood was sampled.
(B) Map of chromosome 4 and the
25 Mb candidate region extending from
base pair 153,990,826 to base pair
179,701,123 on the long arm. This region
contains 496 genes, including GUCY1A3,
whose organization is shown.
(C) The homozygous mutations cosegre-
gating with the affected phenotype in the
three families. All mutations lead to pre-
mature stop codons.cases in Japan are familial. Various patterns of inheri-
tance have been reported, and several whole-genome
linkage studies have been performed for the identification
of MMD genetic loci.5 No mutated gene has yet been
identified within those linked regions. Interestingly,
recent genome-wide association studies have suggested
that RNF213 (MIM 613768), located at 17q25 and
encoding a ring-finger protein, is a MMD susceptibility
gene.6,7
Achalasia is a rare disease characterized by aperistalsis of
the esophageal body and failure of the lower esophageal
sphincter to relax. The idiopathic form is thought to
be caused by a loss of inhibitory innervation in the
myenteric plexus, possibly as a result of an inflammatory
insult to ganglion cells.8 Age at clinical onset in the
idiopathic form is between 25 and 60 years old. However,
there is a rare autosomal-recessive isolated form with an
infancy onset.8 In addition, several familial, early-onset,
syndromic achalasia disorders have been reported, in-
cluding Allgrove syndrome (also called achalasia-addiso-
nianism-alacrima syndrome and triple-A syndrome [MIM
231550]), which is caused by loss-of-function mutations
in AAS (MIM 605378), and two conditions awaitingmolec-
ular characterization, familial visceral neuropathy (MIM
609629 and 243180) and achalasia microcephaly syn-
drome (MIM 200450).386 The American Journal of Human Genetics 94, 385–394, March 6, 2014Herein, we report on three
unrelated consanguineous families
affected by a disease characterized by
the association between a moyamoya
angiopathy and an early-onset acha-
lasia. We show that this disease is
caused by homozygous loss-of-func-
tion mutations in GUCY1A3 (MIM
139396), encoding the a1 subunit ofsoluble guanylate cyclase (sGC), a ubiquitously expressed
heterodimeric enzyme that is the major receptor for nitric
oxide (NO).
Material and Methods
Affected Individuals and Their Families
Three families (F1–F3) including a total of nine individuals affected
by a syndromic condition associating moyamoya with achalasia
were included in this study (Figure 1A and Table 1). All affected
individuals and/or family members from families F1 and F2 pro-
videdwritten informed consent for a genetic analysis in accordance
with the ethical standards of the Comite´ de Protection des Person-
nes Ile de France I. Written informed consent for a genetic analysis
in accordance with Algeria ethical rules was provided by family F3.
Identification of Causative Mutations
Genomic DNA from probands and consenting relatives was ex-
tracted from peripheral-blood leukocytes according to standard
procedures.
Whole-genome linkage analysis was performed with the
Affymetrix GeneChip Human Mapping EA 250K Array (Affyme-
trix). Sample processing and labeling were performed according
to the manufacturer’s instructions on the IGBMC Microarray
and Sequencing Platform. Hybridization was performed with a
GeneChip Hybridization oven 640, washed with the GeneChip
Fluidics Station 450, and scanned with a GeneChip Scanner 3000.
Table 1. Main Characteristics of Symptomatic Members of Families F1, F2, and F3
Family F1 Family F2 Family F3
II-1 II-3 II-1 II-2 IV-8 IV-9 IV-2a IV-4a IV-5a
Gender male male female female male male male male female
Current age (age at death) in years 22 30 10 5 9 8 23 18 (3)
Achalasia (age at onset at diagnosis in months) yes (0) yes (0) yes (4) yes (0) yes (15) yes (2) yes yes yes
History of stroke (age at onset in months) yes (36) no no yes (7) yes (24) yes (24) no no no
Moyamoya or other intracranial angiopathy yes no no yes yes yes – – –
Anterior circulation involvement yes – – yes yes yes – – –
Posterior circulation involvement yes – – yes no no – – –
Hypertensionb yes yes yes yes NA NA – – –
Malignant hypertension no yes no no NA NA – – –
Raynaud phenomenon no yes no yes NA NA – – –
Livedo reticularis no no no yes NA NA – – –
Platelet number low normal normal normal NA NA – – –
Platelet-aggregation analysis abnormal abnormal NA NA NA NA – – –
Bleeding time normal normal NA NA NA NA – – –
Clinical history of abnormal bleeding no no no no NA NA – – –
The following abbreviation is used: NA, not available.
aFamily F3 lived in a remote region of Algeria where the health-care system is limited. No extra digestive investigation was realized in F3 IV-2, F3 IV-4, or F3 IV-5 in
the absence of neurological symptoms.
bThe diagnosis of hypertension was based on ABPM if blood-pressure measurements taken in the clinic were normal.Genotypes were called with the GeneChip Genotyping Analysis
Software (GTYPE v.4.1, Affymetrix) and Genotyping Console
(GTC v.4.0, Affymetrix). All data handling was performed with
the graphical user interface ALOHOMORA. We verified sample
genders with the CheckGender software. The program Pedstats
(MERLIN package) was used for the detection of Mendelian and
non-Mendelian errors; unlikely genotypes for related samples
were deleted. Under the assumption of autosomal-recessive inher-
itance, a penetrance of 95%, a disease allele frequency of 0.0001,
and no phenocopy, parametric multipoint linkage analysis was
carried out with MERLIN v.1.1.2. Allele frequencies and a genetic
distance map were obtained from Affymetrix. LOD-score results
were obtained with R software.
Exons of DNA samples were captured with in-solution enrich-
ment methodology (SureSelect Human All Exon Kit v.2, Agilent)
with the company’s biotinylated oligonucleotide probe library
(Human All Exon v.2 44 Mb, Agilent). Each genomic DNA frag-
ment was then sequenced on a sequencer as 75 bp paired-end
reads (Illumina HISEQ, Illumina). Image analysis and base calling
were performed with Real Time Analysis Pipeline v.1.8 with
default parameters (Illumina). The bioinformatic analysis of
sequencing data was based on a pipeline (Consensus Assessment
of Sequence and Variation [CASAVA] v.1.7, Illumina). CASAVA per-
forms alignment against the human reference genome (hg18,
UCSC Genome Browser), calls the SNPs on the basis of the allele
calls and read depth, and detects variants (SNPs and indels).
Genetic-variation annotation was performed by an in-house pipe-
line (IntegraGen), and results were provided per sample in tabu-
lated text files. Exome analysis was performed with a shell script
and the genetic-variation-annotation files. Variants were filtered
with the use of linkage data, annotation information (missense,The Amenonsense, splice-site, and indel frameshifts), control exomes (20
control exomes and 8 HapMap exomes), and dbSNP v.130.
All exons and flanking intron sequences of GUCY1A3 were
amplified and sequenced by standard methods (Table S1, available
online).Platelet Analyses
Platelet Preparation
Venous blood from individuals F1 II-1 and F1 II-3 was collected in
10% (vol/vol) ACD-A buffer (75mM trisodium citrate, 44mMcitric
acid, 136mMglucose, pH 4) for experimentswithwashed platelets.
Platelet-rich plasma was obtained by centrifugation (100 3 g for
15min at 20C), and platelets were isolated by differential centrifu-
gations. The platelet pellet was resuspended in Tyrode’s buffer
(5 mMHEPES, pH 7.4, 137 mMNaCl, 2 mMKCl, 12 mMNaHCO3,
0.3mMNaH2PO4, 1mMMgCl2, 2mMCaCl2, and 55mMglucose).
Immunoblotting
Immunoblot analysis of sGCa1, sGCa2, and sGCb1 expression
was performed with 0.4 3 107 washed platelets from individuals
F1 II-1 and F1 II-3 and two healthy controls. Polyclonal antibodies
specific to sGCa1, sGCa2, and sGCb1 and monoclonal antibodies
specific to a-tubulin and b-actin were purchased from Sigma
(G4280 [sGCa1], T9026 [a-tubulin], and A5441 [b-actin]), Santa
Cruz Biotechnology (sc-20954 [sGCa2]), and Cayman Chemical
(160897 [sGCb1]). In addition, lung lysates (12 mg) from wild-
type-sGCa1 C57Bl6 mice and sGCa1-deficient mice were used as
control samples.
Washed platelets were incubated with a range of PROLI
NONOate as indicated. After 5 min at 37C, platelets were lysed
in denaturing buffer (50 mM Tris, 100 mM NaCl, 50 mM NaF,rican Journal of Human Genetics 94, 385–394, March 6, 2014 387
5 mM EDTA, 40 mM b-glycerophosphate, 100 mM phenyllarsine
oxide, 1% sodium dodecyl sulfate, 5 mg/ml leupeptin, 10 mg/ml
aprotinin, pH7.4). Proteinswere separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes. Membranes were incubated
with antibodies. Immunoreactive bands were visualized with en-
hanced chemiluminescence-detection reagents (Perbio Science).Functional Analyses
Reagents
Equine type I collagen and ADP were obtained from Kordia. Hu-
man purified von Willebrand Factor (VWF) was a kind gift from
the Laboratoire Franc¸ais de Fractionnement et Biotechnologies.
D-Phe-Pro-Arg chlormethylketone dihydrochloride (PPACK) was
from Calbiochem (VWR). Leupeptin, aprotinin, apyrase grade
VII, prostaglandin E1, and rhodamin-6G were from Sigma-Aldrich.
The ATP determination kit was purchased from Promega. PROLI
NONOate was obtained from Cayman Chemical Company. Poly-
clonal antibodies against Phospho-VASP (Ser239 and Ser157) were
fromCell Signaling Technology. Themonoclonal antibody against
VASP was purchased from Becton Dickinson.
Platelet Aggregation
Platelet aggregationofwashedplateletswasmonitoredbymeasure-
ment of light transmission through the stirred suspension of plate-
lets (2.53 108 platelets/ml) for 3 min with the use of a Chronolog
aggregometer (Coultronics). Platelet aggregation was triggered by
the additionofADP, as described in theResults. Platelet aggregation
was assessed as the percent change of light transmission with
respect to the blank (buffer without platelets) set at 100%.
Platelet Dense-Granule Secretion
Dense-granule secretion was quantified by measurement of ATP
release during platelet aggregation. After 3 min, platelet aggrega-
tion was stopped by the addition of cold EDTA (16 mM) and sub-
sequent centrifugation (12,000 3 g for 1 min). ATP release was
quantified by an ATP determination kit with luciferase and its sub-
strate, D-luciferin, according to the manufacturer’s instructions.
Light emission was assessed with a luminometer (Fluostar Optima,
BMG Labtech). Dense-granule secretion was expressed as pmoles
of ATP released.In Vitro Platelet Adhesion under Flow Conditions
Platelet adhesion was evaluated in a whole-blood perfusion assay
on a matrix of fibrillar collagen and VWF under venous (shear
rate of 300 s1) or arterial (shear rate of 1,500 s1) shear conditions
as previously described.9 In brief, PPACK (80 mM) anticoagulated
blood from cases or controls was incubated with rhodamine 6G
(10 mg/ml) for 5 min and then perfused on glass coverslips pre-
coated overnight at 4C with fibrillar equine type I collagen
(50 mg/ml) or purified human VWF (5 mg/ml) at a shear rate of
300 or 1,500 s1 with a syringe pump (Fisher Scientific) in a
parallel-plate perfusion chamber. Platelet adhesion was recorded
with an inverted epifluorescence microscope (Nikon Eclipse
TE2000-U) coupled to the Metamorph 7.0r1 software (Universal
Imaging Corporation) and was quantitated by assessment of the
mean percentage of the total area covered by platelets.Results
Clinical Features of Families F1–F3
In family F1, two male siblings born from healthy consan-
guineous parents and with unremarkable familial and pre-388 The American Journal of Human Genetics 94, 385–394, March 6natal histories (Figure 1A and Table 1) were both diagnosed
with early-onset achalasia after repeated episodes of regur-
gitations during their first days of life. The diagnosis was
based on the association between a megaesophagus on
esogastroduodenal transit (EGT) and a typical pattern of
achalasia on esophageal manometry. Heller myotomy
was performed in both of them when they were 4 months
(F1 II-1) and 3 years (F1 II-3) old. Individual F1 II-1 pre-
sented with two ischemic strokes at ages 3 and 9 years
(Figure 2). Digital subtraction angiography (DSA) showed
affected vessels in both anterior and posterior circulation
and occlusion of terminal ICA bifurcations and the P2
segment of the right posterior cerebral artery. A fine
vascular network typical of moyamoya vessels was
observed close to the occluded arteries (Figure 2). After
the second stroke, he became handicapped by left hemipa-
resis and opercular syndrome. Swallowing difficulties sec-
ondary to both achalasia and stroke led to gastrostomy at
age 10 and to pneumatic dilation of the cardia at age 22.
The individual was treated efficiently by nicardipine
and perindopril for hypertension from the age of 20.
Ultrasound examination of the heart, kidneys, and renal
arteries was normal. Platelet count was repetitively
around 100,000/ml, and bleeding time was 4 min (normal
range ¼ 4–8 min). There was no clinical history of
abnormal bleeding. Individual F1 II-3 had a normal social
life and qualified job. Esophageal myotomy was efficient,
and the only persistent symptom was an intermittent
and nonincapacitating dysphagia. He had a history of
extensive Raynaud phenomenon in his fingers, hands,
toes, feet, and nose since childhood and did not show sig-
nificant abnormality upon capillaroscopy examination.
He reported erectile dysfunction since adolescence. At 25
years of age, he had an episode of malignant hypertension
complicated by severe retinopathy, posterior ischemic
optic neuropathy, and renal insufficiency (clearance ¼
50 ml/min) (Figure S1). Echocardiography was normal.
Kidneys were small and renal arteries were normal upon
ultrasound examination. A kidney biopsy was not per-
formed. Finally, when he was 28 years old, imaging of
the brain and intracranial arteries was normal (Figure 2).
In family F2, two female siblings born from two healthy
first cousins were affected (Figure 1 and Table 1). Individual
F2 II-1 regurgitated daily after the age of 4 months. Recur-
rent stenoses of different segments of the esophagus lead-
ing to repeated pneumatic dilations between age 11 and
16 months were observed on esophagogastroduodeno-
scopy. The diagnosis of achalasia was established by EGT
and esophageal manometry at 2.5 years of age (Figure 3).
Heller myotomy was performed at age 3. Histological ex-
amination of themyectomy specimen showed that fibrosis
of the myenteric plane was abnormal in comparison to a
normal postmortem esophagus of the same age (Figure S2).
There was no inflammatory infiltrate. Smooth-muscle cells
in themuscular layer andwithin the vascular wall were not
damaged. The myenteric plexus was seen between the
muscle layers and, compared to the control myenteric, 2014
Figure 2. Moyamoya Angiopathy and Other Intracranial Angiopathy in Families F1, F2, and F3
(A and B) DSA in individual F1 II-1 and intracranial magnetic resonance angiography (MRA) in individual F2-II showed an association be-
tween severe steno-occlusive lesions (red arrows) of the terminal segment of ICAs (A) and posterior cerebral arteries (PCAs, B) and typical
moyamoya neovessels (red arrow heads). Cerebral MRA did not detect any intracranial angiopathy (white arrows) in F1 II-3 or F2 II-1. In
F3 cases, DSA showed the left ICA in both frontal (A) and lateral (B) views. In F3 IV-8, occlusion of the terminal left ICA (red arrows) and
pial anastomosis arising from the left PCA (white arrows) were seen. In individual F3 IV-9, an unusual unilateral intracranial arteriopathy
was observed with long arterial stenosis of the left middle cerebral artery (MCA, red arrows).
(C) Brain MRI revealed bilateral hemispheric infarcts in individuals F1 II-1, F2 II-2, and F3 IV-8 and a left cortical MCA infarct in indi-
vidual F3 IV-9.plexus, had preserved number and normal cytological
aspect of ganglia cells. Fibrotic changes without any intra-
nuclear inclusion in neurons were also detected in nerves.
The individual never had neurological symptoms. Her
brain and intracranial arteries were normal at MRI exami-
nation (Figure 2). Stage 1 hypertension was detected by
ambulatory blood-pressure monitoring (ABPM) at age 10.
Individual F2 II-2 had regurgitation episodes from the
day she was born. Despite Heller myotomy, nutrition was
only possible by gastrostomy. She presented several epi-
sodes of right hemiparesis followed by generalized seizure
at the age of 7 months and presented 3 weeks later with
a severe left hemiplegia. MRI showed two large infarcts in
both hemispheres. Intracranial magnetic resonance angi-
ography (MRA) showed severe stenosis of both ICA bifurca-
tions associated with moyamoya vessels on the left side
(Figure 2). Echocardiography was normal. Diagnosis of
achalasia was made when she was 11 months old on the
basis of EGT results and the presence of a typical pattern
of esophageal manometry (Figures 3B and 3D). She had
livedo and recurrent episodes of Raynaud phenomenon.
At the age of 3 years, she had an intense episode of micro-
vascular dysfunction with cyanosis after cerebral imaging
was obtained under general anesthesia with Sevoflurane.
These symptoms resolved spontaneously in a few hours.
During her last follow-up visit at age 4.5 years, she re-
mained severely disabled. She was able to pronounce
only few words and to stay seated only for a few seconds.
There was no additional ischemic lesion, but increasedThe Amearterial stenosis was detected in both anterior and posterior
circulation upon MRI examination. Finally, ABPM realized
at age 5 revealed a stage 1 hypertension.
In family F3, five siblings born fromhealthy consanguin-
eous parents were clinically symptomatic (Figure 1). All of
themwere diagnosedwith early-onset achalasia and treated
by Heller myotomy. Only F3 IV-8 and F3 IV-9 had a history
of stroke. This family lived in a remote region of Algeria
where the health-care system is limited. No extra digestive
investigation was realized in F3 IV-2, F3 IV-4, or F3 IV-5 in
the absence of neurological symptoms. Individual F3 IV-8
experienced a right hemiparesis associated with aphasia
when he was 2 years old and a contralateral hemiparesis at
age6.MRI showedbilateral infarcts inmiddle cerebral artery
(MCA) and anterior cerebral artery (ACA) territories. DSA
showed bilateral moyamoya angiopathy of the anterior
circulation (Figure 2). Individual F3 IV-9 was operated on
for achalasia at the age of 2 months. He experienced two
episodes of transient right hemiparesis at the age of 4 years
and 7 months, which revealed a left MCA infarct and an
unusual intracranial angiopathy characterized by long arte-
rial stenosis of the left MCA and ACA (Figure 2).
Identification of the Causative Mutations
To identify the underlying genetic defect in this disorder,
we conducted a genome-wide linkage scan in family F3.
Multipoint linkage analyses performed with MERLIN
displayed four regions that reached the maximum theoret-
ical LOD score (max LS ¼ 2.159) in chromosomalrican Journal of Human Genetics 94, 385–394, March 6, 2014 389
Figure 3. Achalasia Pattern in Individ-
uals F2 II-1 and F2 II-2
EGTs in individuals F2 II-1 (A) and F2 II-2
(B) showed a megaesophagus suggestive
of achalasia. In individual F2 II-2, normal
esophageal peristalsis (C) and the achalasia
pattern (D) as observed in high-resolution
manometry with esophageal-pressure-
topography analysis are illustrated. An
esophageal-manometry probewas inserted
through the nostril. The probe (diameter
4.2 mm) was composed of closely spaced
pressure sensors (1 cm apart). Time is on
the x axis, and distance from the nostrils
is on the y axis. Each pressure is associated
with a color (right legend). Before swallow-
ing (black arrow), two high-pressure zones
were identified: the upper esophageal
sphincter (UES) and the esophagogastric
junction (EGJ). During swallowing, a
pharyngeal contraction occurred and UES
pressure decreased. The EGJ relaxed, and
peristaltic esophageal contraction was
observed. In individual F2 II-2 (D), no
EGJ relaxation was observed during swal-
lowing. Pressure increased simultaneously
in the esophageal body.regions 2q21.1–q24.3, 4q31.3–q34.3, 12p13.33–p13.31,
12q24.31–q24.32, and Xq27.3–q28 (max LS ¼ 1.743)
(Figure S3 and Table S2; GEO accession number
GSE48099). The linked regions had a cumulated physical
size of 84.5 Mb and included a total of 496 known genes
(hg18, UCSC Genome Browser).
Whole-exome sequencing in individuals F3 IV-8 and
F2 II-2 revealed that both of them were homozygous for
variants located in GUCY1A3, the sole gene located in one
of the candidate regions and found to be mutated in both
individuals (Figures 1B and 1C and Table S3). The DNA
of individual F3 IV-8 showed a G>A splice-site
mutation (c.1086 þ1G>A [RefSeq accession number
NM_000856.4]) at genomic position chr4: 156,851,854
(hg18); because no RNA or protein lysates were available,
the consequences on the protein could not be checked. At
chr4: 156,851,812, a C>T nonsense mutation (c.1045390 The American Journal of Human Genetics 94, 385–394, March 6, 2014C>T [p.Arg349Ter]) was identified in
individual F2 II-2. Both variants were
confirmed by Sanger sequencing.
They both cosegregated with the
affected phenotype in families F3
and F2 as an autosomal-recessive trait.
Neither variant has been found in the
NHLBI Exome Sequencing Project
Exome Variant Server or in dbSNP.
Sanger sequencing of GUCY1A3
in family F1 identified a 1 bp
homozygous deletion (c.1170delA
[p.Glu391LysfsTer19]) leading to a
premature stop codon at codon 408
in the two affected siblings.All together, these data strongly suggest that this syn-
dromic condition is caused by loss-of-function mutations
in GUCY1A3, which encodes the a1 subunit of the hetero-
dimeric sGC. sGC is the major receptor for NO, and its
activation generates cyclic guanosine monophosphate
(cGMP), a second messenger regulating a number of phys-
iological functions in the cardiovascular, neuronal, and
gastrointestinal systems.10–13
Functional Consequences of GUCY1A3 Mutations
Two sGC isoforms exist, sGCa1b1 and sGCa2b1, and they
have similar catalytic activity but differ in their subcellular
and tissue localization. The known absence of the a2b1 iso-
form in platelets and the easy access to those cells led us to
use them to investigate the consequences of GUCY1A3
mutations. Immunoblot analysis of platelet lysates from
affected individuals F1 II-1 and F1 II-3 did not detect any
Figure 4. Functional Analysis of Mutations with the Use of Individuals’ Platelets
(A) Aggregation and secretion of washed platelets from individuals F1 II-1 and F1 II-3 was initiated by the addition of various concen-
trations of ADP (2.5–7.5 mM). Aggregation was expressed as the percent change in light transmission; the value for the blank (buffer
without platelet) was set at 100%. ATP was expressed as the amount of ATP released (pmoles).
(B) Whole blood was perfused over collagen (50 mg/ml) or purified human VWF (5 mg/ml) at 300 or 1,500 s1 in a parallel plate chamber.
After 5 min, platelet adherence was observed under an epifluorescence microscope (original magnification 203). The total area covered
by platelets was expressed as the mean 5 SEM of one independent experiment performed in quadruplicate. **p < 0.01, ***p < 0.001
(paired Student’s t test).sGCa1, whereas this protein was readily detected in
platelet lysates from healthy controls (Figure S4A). The
loss of sGCa1 was accompanied by a complete loss of
sGCb1 (Figure S4B). The sGCa2 isoform was absent in hu-
man platelets from both controls and affected individuals
(Figure S4C).
To determine the impact of the loss of sGC on platelet
functions, we first investigated platelet aggregation andThe Amesecretion induced by a G-protein-coupled-receptor agonist
(ADP). Platelet aggregation and secretion induced by ADP
were impaired for all concentrations tested (2.5–5 mM) (Fig-
ure 4A). Adhesion and thrombus formation on collagen
and VWF, involving GPVI and the GPIb-IX-V receptor
complex, respectively, were then tested in whole-blood
perfusion assays. For these experiments, platelet counts
in blood were normalized. After 5 min of perfusion atrican Journal of Human Genetics 94, 385–394, March 6, 2014 391
300 s1, the surface area covered by F1 II-1 and FI II-3 plate-
lets on collagen was significantly decreased (56.7% and
55.2% of controls, respectively; p < 0.01) (Figure 4B).
Adhesion of F1 II-1 and FI II-3 platelets on a VWF matrix
after 5 min at 1,500 s1 was also significantly decreased
(63.3% and 33.5% of controls, respectively; p < 0.001).
Finally, the levels of collagen receptors (b1 and GPVI)
and VWF receptor (GPIba) aIIbb3 were normal in platelets
from cases (data not shown). All together, these results
show a stimulatory role of sCG in platelet activation.
We next examined platelet activation in the presence of
NO donors. First, unstirred washed platelets were incu-
bated for 5 min at 37C with various concentrations of
PROLI NONOate (1–10 mM). The activity of PKG, reflecting
the effect of NO-cGMP synthesis, was followed by the
phosphorylation of vasodilatator-stimulated phosphopro-
tein (VASP). VASP was phosphorylated at residues Ser239
and Ser157 in control platelets preincubated with PROLI
NONOate; in contrast, VASP phosphorylation was absent
in platelets from affected individuals (F1 II-1 and F1 II-3),
no matter the concentrations of PROLI NONOate (Fig-
ure S5A). Second, we investigated the effect of this
NO donor by using a high concentration of collagen
(2 mg/ml) (Figure S5B). Inhibition of collagen-induced
platelet aggregation and secretion by PROLI NONOate
was observed in control platelets, and the maximal inhibi-
tion was obtained with 5 mM of PROLI NONOate (Fig-
ure S5B). In contrast, this NO donor had no inhibitory
effect (F1 II-1) or a weak effect (F1-II-3: 10%) on aggrega-
tion and secretion in platelets from affected individuals.
The same results were obtained with sodium nitroprusside,
another NO donor. All these data strongly suggest that,
upon these experimental conditions, NO mediates inhibi-
tion of collagen-induced platelet aggregation and secretion
via sGC.Discussion
Herein, we report on three unrelated families including
nine individuals with a disorder characterized by the asso-
ciation between a severe intracranial angiopathy (4/9) and
early-onset achalasia (9/9). In these three consanguineous
families, we identified homozygous GUCY1A3 mutations
cosegregating with the affected phenotype and leading to
a complete loss of the a1b1 NO-sensitive sGC.
GUCY1A3 encodes the a1 subunit of the most abundant
sGC isoform in the vascular system, where it regulates
smooth-muscle cell relaxation and vascular tone.10,11 The
most surprising finding of this study is the cerebrovascular
selectivity of vascular lesions. Indeed, 3/9 of our individ-
uals presented with a bilateral moyamoya angiopathy,
and an additional one showed a severe intracranial angiop-
athy without a moyamoya neovessel network. The sole
other vascular symptoms of these individuals were an in-
crease in systemic blood pressure in four individuals, Ray-
naud phenomenon in two individuals, and livedo in one392 The American Journal of Human Genetics 94, 385–394, March 6individual. In mice, constitutive ablation of the a1 subunit
leads to either no overt phenotype or a very mild, hyper-
tension phenotype.14,15 The cerebrovascular anatomy of
thesemice has been reported to be normal, and no cerebro-
vascular phenotype has been observed in physiological
conditions.16 How the loss of sGC could possibly lead to
moyamoya angiopathy would be speculative at this point.
However, given the current knowledge of the role of the
NO-sGC pathway in cerebrovascular regulation, we raise
the hypothesis that an alteration of this pathway might
lead to abnormal vascular remodeling at highly sensitive
sites with disrupted laminar flow.Moyamoya-affected indi-
viduals’ stenotic lesions are located at the terminal portion
of ICAs, where they bifurcate into middle and anterior ce-
rebral arteries. Histopathology shows an important but
asymmetrical fibrocellular intima thickening composed
of smooth-muscle actin-positive cells and an attenuation
of the media.17 The intima-media thickness in carotid ar-
teries of healthy subjects and the neointimal growth in
pathological conditions, including moyamoya, have
been shown to be inversely correlated with shear
stress.18–21 In arterial bifurcations, shear stress is modified
and a main function of NO signaling is to normalize shear
stress. In our affected individuals, loss of a1b1 sGC in
smooth-muscle cells did not allow them to respond
adequately to NO, and abnormal remodeling therefore
occurred at bifurcation and curvature regions. Additional
factors related to the specificity of each vascular bed,
such as the residual level of a2b1 sGC, might explain the
predominance at ICA bifurcations.
The other main phenotype of our individuals was an
achalasia that develops very early in life. Idiopathic acha-
lasia in adults has been related to a loss of inhibitory nitrer-
gic neurons of the lower esophagus, and such a loss is
possibly related to inflammatory or autoimmune in-
sults.8,22,23 Very few pathological studies have been con-
ducted in pediatric cases, but of those performed, most
have been in Allgrove syndrome cases.24 Lesions in indi-
viduals with Allgrove syndrome are characterized by the
association of a fibrosis of the plane between the circular
and longitudinal muscular layers, a decrease in myenteric
ganglia, and an absence of neuronal NO synthase. Our
case was characterized by a fibrosis of the intermuscular
plane and nerves without any decrease in the density of
ganglia cells or inflammation of the esophagus. All
together, these data strongly suggest that achalasia is
caused by a failure of the NO signaling pathway to relax
the lower esophageal sphincter. In our cases, this failure
was caused by a loss of sGC, the main NO receptor in
esophageal smooth-muscle cells. In other cases, such as
idiopathic adult achalasia, it might be linked to an
acquired NO-production defect that is caused by a loss of
nitrergic ganglia cells as a result of various insults.
In mutation carriers, the penetrance of achalasia is 100%
and the penetrance of moyamoya is close to 50%, which
strongly suggests that some isolated cases with early-onset
achalasia might harbor mutations of this gene and, 2014
therefore should undergoGUCY1A3mutation screening. If
a deleterious mutation in GUCY1A3 is identified, noninva-
sive cerebrovascular imaging, such as 3D time-of-flight
MRA, would be necessary for detecting asymptomatic
moyamoya angiopathy. The detection of an intracranial
angiopathy in those cases might have important clinical
implications, especially when a surgical treatment of
achalasia is considered. Indeed, moyamoya is associated
with a high risk of cerebral ishemic complication even
after minor surgical procedures, and specific measures
are needed for reducing the risk of periprocedural
morbidity.25 Achalasia has also been reported in mice
defective in neuronal NO synthase,26 suggesting that addi-
tional genes involved in the NO-sGC signaling pathway
might be involved in this heterogeneous condition and
in nonsyndromic moyamoya.
NO and sGC are generally recognized as major regulators
of platelet functions.11–13 NO donors play an inhibitory
role in platelet activation, and this effect is mainly sGC
dependent. For this reason, sGC is generally believed to
be a negative regulator of platelet activation. Herein, we
have shown that in both individuals tested, loss of
sGCa1b1 in platelets led to a defect in platelet activation,
strongly suggesting that sGC does in fact have a stimula-
tory role. These findings are consistent with those ob-
tained recently in mice in which sGCb1 was selectively
ablated in megakaryocytes.12 Indeed, deletion of sGC in
the platelets of these mice caused a marked decrease in
agonist and NO-dependent platelet activation and an
increased bleeding time. The reduced bleeding time
observed in whole-body-sGC-depleted mice by Dangel
et al. might have been caused by the compound effect of
sGC loss in all cells, including vascular smooth-muscle
cells, on vasoconstriction.12,13 However, with regard to
clinical care, none of the mutated carriers in our families
presented with spontaneous or surgically induced bleeding
symptoms, and how this platelet defect could possibly in-
fluence the vascular phenotype, particularly the stroke
phenotype, of the individuals remains unknown.
The NO-sGC-cGMP pathway is a key signal-transduction
pathway that is a major target for pharmacological inter-
ventions.27 Even though the mechanisms underlying the
disease reported herein are not yet understood, the identifi-
cation of loss-of-function causative alterations in sGCa1
provide clues to potential treatment options in those indi-
viduals. Given that the mutations lead to a complete loss
of themajor sGC isoform (sGCa1b1), one possibility would
be to take advantage of the residual minor isoform
(sGCa2b1) present inmany tissues. Drugs such as PDE5 in-
hibitors, which inhibit the degradation of the cGMP pro-
duced through sGCa2b1, would be useful. Indeed, a small
amount of sGCa2b1 (6% of total sGC) in the aorta is able
to compensate for sGCa1b1 loss inmice.14 In this situation,
compounds such as Sildenafil might possibly improve
some of the manifestations of the individuals, particularly
for acutemanifestations, such as painful Raynaudphenom-
enon.28 It can also be helpful to solve erection problemsThe Ame(detected in the oldest individual of our series). These acute
manifestations could also possibly be improved by NO
donors, provided that a certain amount of sGCa2b1 is pre-
sent in relevant cells. Another possibility would be to use
components that would stimulate and/or activate the
sGCa2b1 isoform. In cells where no sGCa2b1 is present,
intervention at downstream targets should be investigated.
This will require identification of the relevant downstream
pathways, probably in animal models.
In summary, we report on an autosomal-recessive dis-
ease associating amoyamoya angiopathy with an achalasia
and have shown that this disease is caused by loss-of-func-
tion mutations in GUCY1A3, the gene encoding one of the
subunits of sGC, the major receptor for NO. Our data
suggest that alterations of this pathway might lead to
an abnormal vascular-remodeling process in sensitive
vascular areas, such as ICA bifurcations. They also provide
treatment options for affected individuals, and these
should be carefully and cautiously evaluated.
These data also suggest that investigation of this gene
and other genes encoding the various members of the
NO-sGC-cGMP pathway is warranted in both pure early-
onset achalasia and nonsyndromic moyamoya.Supplemental Data
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